"From the Sanger Institute’s first spin-out to a leading therapeutic antibody company …working with partners to provide novel solutions in drug and vaccine development. Using our unique technology, we rapidly develop broad diversity, high quality human antibodies against challenging targets.

Kymab was founded by Professor Allan Bradley, FRS, in 2010, based on developments in his laboratory at the WELLCOME TRUST SANGER INSTITUTE.

We raised $30m of equity financing in 2010 from the Wellcome Trust Investment Division to enable the development of our Kymouse™ platform and create a portfolio of therapeutic assets.

In a paper published in Nature Biotechnology in 2014, our researchers showed that our Kymouse™ technology yields an antibody library constituted from 100 trillion different antibodies. From this deep library, we can select rare high-quality antibodies that can be developed into therapeutics.

In 2014, the Bill and Melinda Gates Foundation and THE WELLCOME TRUST made a Series B investment of $40 million in Kymab, followed by further investment in 2015 from WOODFORD PATIENT CAPITAL TRUST PLC and MALIN CORPORATION, which raised $50 million. In November 2016, Kymab secured US$100 million (£81 million) in Series C financing, led by new investors ORI HEALTHCARE FUND L.P., with participation by SHENZHEN HEPALINK PHARMACEUTICAL CO., LTD, as well as follow-on investments from existing shareholders.

Kymab has around 100 staff and is headquartered on the Babraham Research Campus, three miles from Cambridge Biomedical Campus, the MRC Laboratory of Molecular Biology and Addenbrooke’s Teaching Hospital.

Our vision is to be a global biopharmaceutical company, an inspirational home of molecular immunology driving the development of novel drug substances.

Our mission

Fusing passion with compassion, Kymab’s mission is:
• To realise fully the value of antibodies developed using the Kymouse™ platform
• To deliver modern medicines on a unique and proven platform
• To bring hope to patients with high unmet needs
• To treat the world’s diseases, bringing societal benefit
• To be an effective global partner in ameliorating global disease
• To realise unique opportunities for partners and value for investors from our unique approach

Our partners
• MD ANDERSON CANCER CENTER
• BILL & MELINDA GATES FOUNDATION
• HEPTARES
• NOVO NORDISK"